Cargando…
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Immune checkpoint inhibitors are becoming standard treatments in several cancer types, profoundly changing the prognosis of a fraction of patients. Currently, many efforts are being made to predict responders and to understand how to overcome resistance in non-responders. Given the crucial role of m...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393010/ https://www.ncbi.nlm.nih.gov/pubmed/32793228 http://dx.doi.org/10.3389/fimmu.2020.01590 |